Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea | NCT01976611 | Trialant
CompletedObservationalUpdated Apr 8, 2015
Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea
ClinicalTrials.gov ID
NCT01976611
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Observational
Enrollment
402Actual
Last Update Posted
Apr 8, 2015Estimated
Start Date
Jun 2012
Primary Completion Date
Feb 2015Actual
Completion Date
Feb 2015Actual
Brief Summary
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat Chronic Migraine in clinical practice.
Migraine Disorders
Headache
botulinum toxin Type A
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients treated with botulinum toxin Type A for chronic migraine in clinical practice.